Interaction Between Saw Palmetto and Rosuvastatin (Crestor)

Pharmacokinetic Considerations

Rosuvastatin undergoes minimal hepatic metabolism (≈ 10 % via CYP450 enzymes), making it unlikely to be affected by herbal products that influence CYP pathways, such as saw palmetto. 1
Saw palmetto does not inhibit the major cytochrome P450 enzymes (CYP2D6 or CYP3A4) that metabolize many drugs, as demonstrated in a controlled study of healthy volunteers receiving 320 mg daily for 14 days. (Although the study is cited elsewhere, the specific citation is omitted here because it is marked “ignore ref”).

No drug‑interaction reports between saw palmetto and rosuvastatin have emerged from systematic reviews that pooled data from 26 randomized controlled trials and multiple observational studies, indicating a lack of clinically significant interaction. 2
Theoretical phytoestrogenic activity of saw palmetto could modestly influence prostate‑specific antigen (PSA) levels, but this does not translate into a safety concern when combined with statins. 3

Patients should be monitored for typical statin‑related adverse effects—such as unexplained muscle pain, tenderness, or weakness—that may signal myopathy. [4][5]
Baseline creatine kinase (CK) testing is not required in asymptomatic individuals; CK should be measured only if muscle symptoms develop. 4
Liver function tests should follow standard statin monitoring protocols, as saw palmetto does not increase hepatotoxicity risk when co‑administered. 5

The composition and potency of saw palmetto supplements vary widely across brands due to differing extraction methods and formulations, potentially affecting clinical consistency. 6
Patients should be instructed to promptly report any new muscle symptoms, consistent with standard practice for all statin users, irrespective of concurrent herbal supplementation. [4][5]